Some classic regimes, such as anthracycline-based NAC, anti-Her2 treatment, immune checkpoint inhibitor, and cyclin-dependent kinases 4 and 6 (CDK4/6), proved to have a strong impact on depleting Treg in BC TME through different immunological effects. The gene discussed is ERBB2; the disease is breast cancer.